Euretina Logo, Links to homepage.
Euretina Logo, Links to homepage.

Effect of intravitreal ranibizumab on serous retinal detachment in diabetic macular edema

Author: Emine Doğan (Turkey)

Co-authors: Kübra Özata Gündoğdu, Erkan Çelik, Gürsoy Alagöz,

Purpose

The aim of this study was to evaluate the functional and anatomical results of intravitreal ranibizumab in the treatment of diabetic macular edema (DME) with and without serous retinal detachment (SRD).

Setting/Venue

Retrospective

Methods

Fifty-one eyes treated with three intravitreal injections of ranibizumab for DME with and without SRD were retrospectively analyzed. Patients were divided into two groups according to spectral-domain optical coherence tomography (SD-OCT). Group 1 was consisted of 25 DME patients with SRD, Group 2 was consisted of 26 patients without SRD. After three consecutive intravitreal ranibizumab injections, changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) were analyzed and compared between groups.

Results

The mean age was 64.16 ± 6.43 and, 68.77 ± 7.19 years, respectively (p=0.036). Initial BCVA was 0.55 ± 0.36 logarithm of the minimum angle of resolution (LogMAR), 0.62 ±0.39 LogMAR, respectively (p:0.613). Initial CMT was 548.76 ± 111.62 µm, 446.04 ± 104.10 µm in groups, respectively and it was significantly higher in Group 1 (p=0.001). After three consecutive intravitreal injections of ranibizumab, mean BCVA improved from 0.55 ± 0.36 LogMAR to 0.47 ± 0.30 LogMAR (p=0.281) and CMT decreased from 548.76 ± 111.62 µm to 331.68 ± 165.12 µm (p= 0.000) in Group 1. Mean VA improved from 0.62 ± 0.39 LogMAR to 0.40 ± 0.34 LogMAR (p=0.005) and CMT decreased from 446.04 ± 104.10 µm to 287.25 ± 148.82 µm (p= 0.000) in Group 2. While the decrease in CMT values were similar between the groups, the increase in BCVA was more pronounced in Group 2 after ranibizumab treatment.

Conlusions

Although functional results were not sufficient in DME with SRD; adequate anatomical results could be obtained in DME with and without SRD.

Financial Disclosure

I have no financial relationship

Comments

-

IMPORTANT INFORMATION

Beware of fraudulent websites, emails and hotel booking offers

www.euretina.org is the only official website of the European Society of Retina Specialists.
 
Please be wary of websites, emails from third-party agencies using similar names, addresses or branding and purporting to represent Euretina.
 
This includes websites or companies offering Congress registration, hotel accommodation or travel services while claiming to be affiliated with Euretina.

Should you use any website other than www.euretina.org, or book accommodation through an unauthorised third-party site, you may be charged significantly more than the official registration fee, your hotel booking may not be valid, and you may not be registered for the event at all.
 
If you have any questions in relation to registration or accommodation for the Congress, these should only be directed to [email protected].